College of Chemistry, Sichuan University, Chengdu, China.
Department of Thyroid Surgery, West China Hospital of Sichuan University, Chengdu, China.
J Cell Mol Med. 2021 Sep;25(17):8390-8404. doi: 10.1111/jcmm.16799. Epub 2021 Aug 2.
It is crucial to understand the differences across papillary thyroid cancer (PTC) stages, so as to provide a basis for individualized treatments. Here, comprehensive function characterization of PTC stage-related genes was performed and a new prognostic signature was developed for advanced patients. Two gene modules were confirmed to be closely associated with PTC stages and further six hub genes were identified that yield excellent diagnostic efficiency between tumour and normal tissues. Genetic alteration analysis indicates that they are much conservative since mutations in the DNA of them rarely occur, but changes of DNA methylation on these six genes show that 12 DNA methylation sites are significantly associated with their corresponding genes' expression. Validation data set testing also suggests that these six stage-related hub genes would be probably potential biomarkers for marking four stages. Subsequently, a 21-mRNA-based prognostic risk model was constructed for PTC stage III/IV patients and it could effectively predict the survival of patients with strong prognostic ability. Functional analysis shows that differential expression genes between high- and low-risk patients would promote the progress of PTC to some extent. Moreover, tumour microenvironment (TME) of high-risk patients may be more conducive to tumour growth by ESTIMATE analysis.
了解甲状腺乳头状癌(PTC)各期之间的差异至关重要,可为个体化治疗提供依据。在这里,对 PTC 分期相关基因进行了全面的功能特征分析,并为晚期患者开发了一种新的预后标志物。验证数据集测试也表明,这六个与分期相关的枢纽基因可能是标记四个分期的潜在生物标志物。随后,为 PTC III/IV 期患者构建了一个基于 21 个 mRNA 的预后风险模型,该模型能够有效预测患者的生存情况,具有较强的预后能力。功能分析表明,高低风险患者之间差异表达的基因在一定程度上促进了 PTC 的进展。此外,通过 ESTIMATE 分析,高危患者的肿瘤微环境(TME)可能更有利于肿瘤生长。